Denosumab: a novel antiresorptive drug for osteoporosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25897599.
- Also identified by DOI 10.3949/ccjm.82a.13173.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Denosumab is a novel antiresorptive drug that has been approved for use as a first-line drug for primary and secondary prevention of osteoporotic fractures. The authors discuss the mechanism of action of denosumab, review the evidence for its efficacy and safety in patients with osteoporosis, and offer recommendations for its use in clinical practice.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Lumbar Vertebrae
- Osteoporosis
- Osteoporotic Fractures
- Spinal Fractures
- Thoracic Vertebrae